Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapyTraumatic ...

At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...

Luci explained that efforts to secure partnerships, including with government agencies, are ongoing and "will certainly slip into 2026, given the dynamics that are going on in Washington," but ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...

VYNE Therapeutics Inc. has provided an update on its clinical program for VYN202, an oral small molecule BET inhibitor aimed at treating moderate-to-severe plaque psoriasis. Following a clinical hold ...

Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.